Advances in Key Drug Target Identification and New Drug Development for Tuberculosis.
Tuberculosis (TB) is a severe infectious disease worldwide. The increasing emergence of drug-resistant Mycobacterium tuberculosis (Mtb) has markedly hampered TB control. Therefore, there is an urgent need to develop new anti-TB drugs to treat drug-resistant TB and shorten the standard therapy. The d...
| Publicado en: | BioMed Research International pp. 1 - 24 |
|---|---|
| Autores principales: | , , |
| Formato: | pictorial review tables/charts Journal Article |
| Publicado: |
Wiley-Blackwell
2/25/2022
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=155467720&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 155467720 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 23146133 FT2T jtl: BioMed Research International issn: 23146133 maglogo: N pubinfo: dt: 2/25/2022 pid: 480 pub: Wiley-Blackwell place: Malden, Massachusetts artinfo: ui: 155467720 155467720 155467720 10.1155/2022/5099312 155467720 ppf: 1 ppct: 23 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Advances in Key Drug Target Identification and New Drug Development for Tuberculosis. aug: au: Mi, Jie Gong, Wenping Wu, Xueqiong affil: Tuberculosis Prevention and Control Key Laboratory/Beijing Key Laboratory of New Techniques of Tuberculosis Diagnosis and Treatment, Senior Department of Tuberculosis, The 8th Medical Center of PLA General Hospital, Beijing 100091, China sug: subj: Tuberculosis Drug Therapy Antitubercular Agents Therapeutic Use Mycobacterium Tuberculosis Drug Resistance, Microbial Drug Development Diffusion of Innovation Sequence Analysis Molecular Biology Tuberculosis Pathology Pathology, Molecular Drug Evaluation, Preclinical ab: Tuberculosis (TB) is a severe infectious disease worldwide. The increasing emergence of drug-resistant Mycobacterium tuberculosis (Mtb) has markedly hampered TB control. Therefore, there is an urgent need to develop new anti-TB drugs to treat drug-resistant TB and shorten the standard therapy. The discovery of targets of drug action will lay a theoretical foundation for new drug development. With the development of molecular biology and the success of Mtb genome sequencing, great progress has been made in the discovery of new targets and their relevant inhibitors. In this review, we summarized 45 important drug targets and 15 new drugs that are currently being tested in clinical stages and several prospective molecules that are still at the level of preclinical studies. A comprehensive understanding of the drug targets of Mtb can provide extensive insights into the development of safer and more efficient drugs and may contribute new ideas for TB control and treatment. pubtype: Academic Journal doctype: pictorial review tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|